Get the Stockscreener App
25.28
0.36%
0.09
After Hours:
25.28
Edgewise Therapeutics Inc stock is traded at $25.28, with a volume of 1.60M.
It is up +0.36% in the last 24 hours and down -2.84% over the past month.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
See More
Previous Close:
$25.19
Open:
$25.46
24h Volume:
1.60M
Relative Volume:
1.55
Market Cap:
$2.41B
Revenue:
-
Net Income/Loss:
$-115.88M
P/E Ratio:
-16.34
EPS:
-1.5468
Net Cash Flow:
$-104.72M
1W Performance:
-10.13%
1M Performance:
-2.84%
6M Performance:
+34.25%
1Y Performance:
+45.20%
1-Day Range:
$23.84
$26.40
1-Week Range:
$23.84
$30.04
52-Week Range:
$14.90
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Name
Edgewise Therapeutics Inc
Sector
Industry
Phone
720-262-7002
Address
1715 38TH ST, BOULDER
Compare EWTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
25.28 | 2.41B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-22-25 | Initiated | Stifel | Hold |
| Nov-22-24 | Initiated | Evercore ISI | Outperform |
| Mar-07-24 | Initiated | Piper Sandler | Overweight |
| May-01-23 | Initiated | Truist | Buy |
| Aug-25-22 | Downgrade | Goldman | Neutral → Sell |
| Apr-13-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-28-22 | Initiated | Goldman | Neutral |
View All
Edgewise Therapeutics Inc Stock (EWTX) Latest News
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.3%Time to Sell? - MarketBeat
Ratios Uncovered: Breaking Down Edgewise Therapeutics Inc (EWTX)’s Trailing Twelve Months Metrics - The Dwinnex
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference - BioSpace
Edgewise Therapeutics chief scientific officer sells $6,004 in stock By Investing.com - Investing.com South Africa
Edgewise Therapeutics CEO Kevin Koch sells $3,000 in stock By Investing.com - Investing.com South Africa
Scotiabank Begins Coverage on Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics CEO Kevin Koch sells $3,000 in stock - Investing.com
Edgewise Therapeutics chief scientific officer sells $6,004 in stock - Investing.com India
Breakthrough Drug Sevasemten Delivers Positive Results for Becker Muscular Dystrophy Patients - StockTitan
Edgewise Therapeutics Sees Unusually Large Options Volume (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 4.9%Still a Buy? - MarketBeat
Edgewise Therapeutics: More Expensive Now, But Much More Derisked (NASDAQ:EWTX) - Seeking Alpha
Piper Sandler maintains $51 target on Edgewise Therapeutics stock By Investing.com - Investing.com Canada
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Stock Holdings Lessened by Candriam S.C.A. - MarketBeat
Why Is Edgewise Therapeutics Inc (NASDAQ: EWTX) Falling? - Stocks Register
Edgewise Therapeutics (NASDAQ:EWTX) Research Coverage Started at Scotiabank - Defense World
Trend Tracker for (EWTX) - Stock Traders Daily
Q1 EPS Forecast for Edgewise Therapeutics Lowered by Analyst - MarketBeat
Equities Analysts Issue Forecasts for EWTX FY2026 Earnings - MarketBeat
Scotiabank Initiates Coverage of Edgewise Therapeutics (EWTX) with Sector Outperform Recommendation - Nasdaq
Edgewise Therapeutics Sees Unusually High Options Volume (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics' (EWTX) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Scotiabank sets $50 target for Edgewise Therapeutics stock - Investing.com India
Wedbush Lowers Earnings Estimates for Edgewise Therapeutics - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Leerink Partnrs Brokers Decrease Earnings Estimates for EWTX - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Announces Quarterly Earnings Results - MarketBeat
Handelsbanken Fonder AB Purchases Shares of 21,800 Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Ratios Revealed: Decoding Edgewise Therapeutics Inc (EWTX)’s Financial Health - The Dwinnex
Edgewise Therapeutics (NASDAQ:EWTX) Receives Outperform Rating from Royal Bank of Canada - Defense World
Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025 - Joplin Globe
Edgewise Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Edgewise Therapeutics boosted R&D spending in final quarter of 2024 - BizWest
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q4 Total Operating Expenses $45.5M - Marketscreener.com
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q4 Net Loss $0.42 a Share, vs. FactSet Est of $0.37 Loss - Marketscreener.com
Edgewise Therapeutics reports Q4 EPS (42c), consensus (42c) - TipRanks
Edgewise Therapeutics, Inc. SEC 10-K Report - TradingView
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - Business Wire
Can Edgewise's $470M War Chest and Muscular Dystrophy Pipeline Deliver for Biotech Investors? - StockTitan
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Edgewise Therapeutics (EWTX) Shares Cross Below 200 DMA - Nasdaq
Edgewise Therapeutics (NASDAQ:EWTX) Trading 5.9% HigherShould You Buy? - MarketBeat
Edgewise Therapeutics (EWTX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Edgewise Therapeutics Inc Stock (EWTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):